Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

79 results about "Epipodophyllotoxin" patented technology

Epipodophyllotoxins are substances naturally occurring in the root of American Mayapple plant (Podophyllum peltatum). Some epipodophyllotoxin derivatives are currently used in the treatment of cancer. These include etoposide and teniposide. They act as anti-cancer drugs by inhibiting topoisomerase II.

Tumor targeting nano-micelle based on hyaluronic acid as well as preparation and application of tumor targeting nano-micelle

PendingCN113171342AHas triple tumor targeting capabilitiesGrowth inhibitionPhotodynamic therapyNanomedicineDisulfide bondingTumor target
The invention provides a tumor targeting nano-micelle based on hyaluronic acid as well as a preparation method and application of the tumor targeting nano-micelle. An E selectin peptide ligand is connected with chemotherapeutic drugs such as taxanes, camptothecin and podophyllotoxin through disulfide bonds, then the conjugate is connected to carboxyl of hyaluronic acid, and a formed amphiphilic polymer can be self-assembled in an aqueous solution to form primary nano-targeting micelles. Other functional molecules such as chemotherapeutic drugs and/or photosensitizer indocyanine green can be further loaded to form a multifunctional nano-micelle, and the micelle respectively has an active targeting tumor effect mediated by hyaluronic acid and tumor targeting peptide and a passive targeting effect of the nano-micelle EPR effect, and has the characteristic of photothermal photodynamic and chemotherapy synergetic effect; and E-selectin-mediated adhesion between vascular endothelial cells and tumor cells can be competitively inhibited, so that the potential of inhibiting tumor cell metastasis is achieved. The multifunctional nano-micelle is simple and easy to prepare and wide in application range, and has important application value.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY

6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy

The present invention relates to certain purines of the following formulae, which act as topoisomerase II catalytic inhibitors: wherein: J is independently: —H or —NRN1RN2; X is independently: —O—, or —S—; Q is independently: a covalent bond, C1-7alkylene, C2-7alkenylene, C2-7alkynylene, C3-7cycloalkylene, C3-7cycloalkenylene, or C3-7cycloalkynylene; T is independently: a group A1 or a group A2; A1 is independently: C6-14carboaryl, C5-14heteroaryl, C3-12carbocyclic, or C3-12heterocyclic; and is independently unsubstituted or substituted; A2 is independently: —H, —CN, —OH, or —O(C═O)—C1-7alkyl; RN is independently —H or a nitrogen ring substituent; R8 is independently —H or a ring substituent; either: each of RN1 and RN2 is independently —H or a nitrogen substituent; or: RN1 and RN2 taken together with the nitrogen atom to which they are attached form a ring having from 3 to 7 ring atoms; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. These compounds are useful in combination with topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). These compounds are also useful in the treatment of tissue damage associated with extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin.
Owner:BIOCODEX INC

Novel small molecule inhibitor of insulin-like growth factor-1 receptor and application of novel small molecule inhibitor

The invention provides a novel small-molecule inhibitor of an insulin-like growth factor 1 receptor and application of the novel small-molecule inhibitor. The novel small-molecule inhibitor is a derivative of picropodophyllotoxin; fluorine atoms are used for replacing hydrogen atoms at two positions of the left side of picropodophyllotoxin, so that the capacity of molecules penetrating through a blood-brain barrier is improved; meanwhile, deuterium atoms are used for replacing hydrogen atoms, so that the half-life period of the molecules in an organism can be effectively prolonged. The small-molecule inhibitor can be used for preparing drugs for preventing and treating cancers. Compared with picropodophyllotoxin in the clinical test stage at present, the small-molecule inhibitor has higherblood-brain barrier permeability and longer in-vivo half-life while maintaining the action mechanism and biochemical characteristics of picropodophyllotoxin. When used alone, the small-molecule inhibitor can effectively inhibit proliferation and brain metastasis of various tumors, and can be synergistically combined with other anti-cancer drugs, so that proliferation of tumor cells is efficientlyinhibited, and the lifetime is remarkably prolonged.
Owner:ZHEJIANG UNIV

Podophyllotoxin lipid derivative, nano carrier, preparation method thereof, and application of podophyllotoxin lipid derivative and nano carrier in tumor treatment

The invention provides a podophyllotoxin lipid derivative, a nano-carrier, a preparation method thereof and an application of the podophyllotoxin lipid derivative and the nano-carrier in tumor treatment. The podophyllotoxin lipid derivative is prepared by adopting a podophyllotoxin drug mother nucleus as a hydrophobic nucleus, linking a micromolecular hydrophilic group on the podophyllotoxin drug mother nucleus to form the podophyllotoxin derivative, and introducing a highly hydrophobic long-chain fat-soluble substance to play a stabilizing role. The podophyllotoxin lipid nano-carriers with different structures can be synthesized by changing the types and sizes of the small molecules and the fat-soluble substances and the feeding ratio of the fat-soluble substances to the podophyllotoxin derivatives. The podophyllotoxin lipid derivative provided by the invention overcomes the limitations of low solubility and toxic and side effects of podophyllotoxin, and meanwhile, the podophyllotoxin lipid nano-carrier prepared by the invention has a lipid bilayer structure and an acid / enzyme sensitive connecting bond, and has the characteristic of regulating PD-L1 expression; therefore, the product has the application of tumor microenvironment response and immune escape prevention, and has a wide application prospect in the fields of chemotherapy and immunotherapy in tumor treatment.
Owner:DALIAN NATIONALITIES UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products